The value of changes in CRP and ESR for predicting treatment response in rheumatoid arthritis

APLAR Journal of Rheumatology

Volumn 10, Issue 1, 2007, Pages 23-28

  Heidari, Behzad ^a   Heidari, Parham ^b   Tayebi, Muhammad Ebrahim ^c  

^a BABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CRP; ESR; Rheumatoid arthritis; Treatment response

Indexed keywords

C REACTIVE PROTEIN; CHLOROQUINE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; PREDNISOLONE; SALAZOSULFAPYRIDINE;

ACCURACY; ADULT; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; INTERMETHOD COMPARISON; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RELIABILITY; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

EID: 33847786345     PISSN: 02190494     EISSN: 14798077     Source Type: Journal    
DOI: 10.1111/j.1479-8077.2007.00250.x     Document Type: Article

References (25)

1. Wolfe F (1997) Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatiod arthritis. J Rheumatol 24, 1477-85.
2. Devlin J, Gough A, Huisson A, et al. (1997) The acute phase protein and function in early rheumatoid arthritis. C-reactive protein levels correlate with functional outcome. J Rheumatol 24, 9-13.
3. Jansen LM, van der Horst-bruinsma IE, van Schaardenburg D, Bezmer PD, Dijkmans BA (2001) Predictors of radiographic damages in patients with early rheumatoid arthritis. Ann Rheum Dis 60, 924-7.
4. van-Leewen MA, van-Rijswijk MH, Sluiter WJ, et al. (1997) Individual relationship between progression of radiologic al damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 24, 20.
5. Plant MJ, Williams AL, O'Sullivan MM, Lewis PA, Coles EC, Jessop JD (2000) Relationship between time-integrated C-reactive protein levels and radiologic progression in patients with rheumatoid arthritis. Arthritis Rheum 43, 1473-7.
6. Villaverde V, Balsa A, Cantalejo M, et al. (2000) Activity indices in rheumatoid arthritis. J Rheumatol 27, 2576-81.
7. Gulfe A, Geborek P, Saxne T (2005) Response criteria for rheumatoid arthritis in clinical practice: How useful are they? Ann Rheum Dis 64 (8), 1186-9. Epub 2005 M.
8. Pincus T, Sokka T (2005) Complexities in the quantitative assessment of patients with rheumatic diseases in clinical trials and clinical care. Clin Exp Rheumatol 23 (5 Suppl 39), S1-9.
9. Volbink GJ, Voskayl A, Lems W, et al. (2004) Relation between serum trough infliximab levels, pretreatment CRP levels and clinical response to infliximab treatment in rheumatoid arthritis. Ann Rheum Dis 14, [Epub ahead of print].
10. Lacki JK, Samborski W, Mackiewicz S, Mackiewicz U (1995) Do changes in clinical improvement in rheumatoid arthritis patients treated with immunosuppressive drugs reflect the changes in acute phase proteins? Ups J Med Sci 100, 233-42.
11. Cambridge G, Leandro MJ, Edwards JC, et al. (2003) Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48, 2146-54.
12. Hayashi N, Kumagai S (2003) New diagnostic tests for rheumatoid arthritis. Rinsho Byori 51, 1030-5.
13. Dawes PT, Fowler PD, Clarke S, Fisher J, Lawton A, Shafforth MF (1986) Rheumatoid arthritis: Treatment with controls the C-reactive protein and erythrocyte sedimentation rate reduces radiologic progression. Br J Rheumatol 25, 44-9.
14. Arnett FC, Edworthy SM, Bloch DA, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31, 315-9.
15. Prevoo ML, van't Hof M, van Leeuwen M, van de Putte LB, van Riel PL (1995) Modified disease activity scores that include twenty-eight joint counts: Development and validation in a prspective longitudinal study of patients with rheumatoid arthritis. Arthritisrheum 38, 44-8.
16. van Gestel A, Horgsma C, van Riel P (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41, 1845-50.
17. Skogh T, Gustafsson D, Kjellberg M, Husberg M (2003) Twenty eight count diseas axctivity score in recent onset rheumatoid arthritis using C-reactive protein instead of erythrocyte sedimentation rate. Ann Rheum Dis 62, 681-2.
18. Aletaha D, Nell VP, Stamm T, et al. (2005) Acute phase reactant add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Res Ther 7, 796-806.
19. Rau R, Schleusser B, Herborn G, Karger T (1998) Long-term combination therapy of refractory and destructive rheumatoid arthritis with methotrexate (MTX0 and intramuscular gold or other disease modifying antirheumatic drugs compared to MTX monotherapy. J Rheumatol 25, 1485-92.
20. Yildirim K, Karatay S, Melikoglu MA, Gureser G, Ugur M, Senel K (2004) Association between acute phase reactant levels and disease activity in patients with rheumatoid arthritis. Ann Chem Laboratory Sci 34, 423-6.
21. van-Leeuween MA, van-Rijswijk MH, van-der Heidjde DM, et al. (1993) The acute phase response in relation to radiographic progression in early rheumatoid arthritis: A prospective study during the the first three years of the disease. Br J Rheumatol 32 (Suppl 3), 9-13.
22. Wolfe F, Pincus T, O'Dell J (2001) Evaluation and documentation of rheumatoid arthritis disease status in the clinic: Which variables best predict change in therapy. J Rheumatol 28, 1712-7.
23. Moreland LW, Margolies G, Heck LW, et al. (1996) Recombinant soluble tumor nebrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis. J Rheumatol 223, 1849-55.
24. Ward MM (2004) Reliability and sensitivity to change of the erythrocyte sedimentation rate and serum C-reactive protein concentration in rheumatoid arthritis. J Rheumatol 31, 884-95.
25. Dessin PH, Joffe BI, Slanwix AE, (2004) High sensitivity C-reactive protein as a disease activity marker in rheumatoid arthritis. J Rheumatol 31, 1095-7.